Dermatology

Host: Jeffrey S. Weber, MD, PhD
Host: Jason J. Luke, MD, FACP
Host: Ryan Sullivan, MD
Host: Omid Hamid, MD

Approximately 50 - 60% of patients with melanoma have BRAF-activating tumors, meaning they are amenable to treatment with combination BRAF/MEK inhibitors. However, immunotherapy is also a highly effective treatment for patients with BRAF-activating tumors. Given the benefit of both types of therapies in the adjuvant setting, there are uncertainties regarding which adjuvant treatment to offer patients with stage III disease. The critical question revolves around which adjuvant treatment strategy provides the best opportunity for sustained recurrence-free survival.

Report with a jury of your peers to debate the optimal adjuvant treatment approach for a patient with fully resected, stage III BRAF-mutant melanoma. View the persuasive evidence and listen to expert witnesses defend the pros and cons for this high-risk patient population. Cast your polling vote as the case proceeds. We’ll see you in court to render a verdict in an important case with implications for your clinical practice!

Host: Jeffrey S. Weber, MD, PhD
Host: Sapna Patel, MD
Host: Jason J. Luke, MD, FACP

Despite improved prognosis for melanoma patients due to advances in treatment options in recent years, survival rates for patients with metastatic disease remain low. With two mechanistically different immune checkpoint inhibitor combinations available, it is critical that clinicians be able to differentiate among currently approved regimens to inform frontline treatment selection in different patient populations. The crucial question revolves around which target, anti-CTLA-4 versus anti-LAG3, provides the greatest benefit in metastatic melanoma when combined with a PD-1 inhibitor.

Report with a jury of your peers to debate the optimal frontline treatment approach for a patient with unresectable stage IV BRAF-wild type melanoma. View the persuasive evidence and listen to expert witnesses defend the pros and cons for this vulnerable patient population. Cast your polling vote as the case proceeds. We’ll see you in court to render a verdict in an important case with implications for your clinical practice!

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Gil Melmed, MD, MS

The inflammation biosimilar development process uses a stepwise approach with increasing certainty to generate the totality of evidence, which demonstrates the safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed.^1,2 Dive further into the role of totality of evidence in the inflammation biosimilar development and approval process with Dr. Gil Melmed, Director of Inflammatory Bowel Disease Clinical Research at the Cedars-Sinai and Professor of Medicine at Cedars-Sinai and at the David Geffen School of Medicine at University of California, Los Angeles. Dr. Melmed was compensated for participating in this program.

References:

1. US Food and Drug Administration. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry. Published online April 2015. Accessed March 22, 2023. https://www.fda.gov/media/135612/download

2. US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry. Published online April 2015. Accessed March 22, 2023. https://www.fda.gov/media/82647/download

©2023 Amgen Inc. All rights reserved. USA-CBU-81605 5/23

Host: Jennifer Caudle, DO
Guest: Jeran Wadlow
Guest: Josh Elmassian, MBA

Allergan Medical Institute^® has taken a personalized approach to training HCPs in medical aesthetics with the launch of AMI Online. Discover multiple online courses spanning the Allergan Aesthetics portfolio, including content on JUVÉDERM^® VOLUX^® XC. Experience how AMI Online’s evidence-based and progressive training curricula can educate and empower the aesthetics community. Join Dr Jennifer Caudle as she speaks with Jeran Wadlow, Associate Director, Digital at Allergan Medical Institute^® in Irvine, California, and Josh Elmassian, Director of JUVÉDERM^® US Commercial Business and Marketing at Allergan Aesthetics, in Irvine, California.

© 2023 AbbVie. All rights reserved.
JUVÉDERM and its design are trademarks of Allergan Holdings France SAS, an AbbVie company, or its affiliates. All other trademarks are the property of their respective owners.

PRT162857 06/23

Host: Jason J. Luke, MD, FACP
Guest: Tara C. Mitchell, MD

The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.

Host: Raj Chovatiya, MD, PhD
Guest: Martina J. Porter, MD

Two of the biggest trials were recently completed for the use of IL-17 inhibitors for treating hidradenitis suppurative (HS). So what data should we know about? In this episode, Dr. Raj Chovatiya is joined by Dr. Martina Porter, Dermatologist at Beth Israel Deaconess Medical Center and Assistant Professor of Dermatology at Harvard Medical School.

Host: Raj Chovatiya, MD, PhD
Guest: Martina J. Porter, MD

For patients with hidradenitis suppurativa (HS), the exact cause of the condition is still being researched. So what therapies are currently available to treat this painful condition? To discuss what you need to know, Dr. Raj Chovatiya is joined by Dr. Martina Porter, Dermatologist at Beth Israel Deaconess Medical Center and Assistant Professor of Dermatology at Harvard Medical School.

Host: Raj Chovatiya, MD, PhD
Guest: Britt Craiglow, MD

The future looks promising for alopecia areata patients as two JAK inhibitors have been tested in clinical trials while other treatment studies are ongoing. So what should clinicians know about these therapies? Learn more as Dr. Raj Chovatiya speaks to Dr. Britt Craiglow, Adjunct Associate Professor at the Yale School of Medicine and Double Board-Certified Dermatologist with Dermatology Physicians of Connecticut.

Host: Raj Chovatiya, MD, PhD
Guest: Britt Craiglow, MD

Initially approved for the treatment of rheumatoid arthritis, baricitinib is now the first FDA-approved treatment for patients with alopecia areata. So what can patients look forward to with this new therapy? Dive in with Dr. Raj Chovatiya as he’s joined by Dr. Britt Craiglow, Adjunct Associate Professor at the Yale School of Medicine and Double Board-Certified Dermatologist at Dermatology Physicians of Connecticut.

Host: Marshall Miller

This episode of Rub Some Dirt in It is getting curiouser and curiouser. See if you can solve these two cases before host Marshall Miller reveals the rare and unexpected diagnoses.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Justin Cheeley, MD

Proper access to medication can present challenges for the doctor and patient but is necessary to achieve optimal patient outcomes. So how can they work together to eliminate this burden? To discuss this further, Dr. Mary Katherine Cheeley is joined by Dr. Justin Cheeley, Assistant Professor in the Departments of General Internal Medicine and Dermatology and the Director of Inpatient Dermatology at Emory School of Medicine.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Justin Cheeley, MD

Patients with IBD, arthritis, or other disorders of the immune system may be at a higher risk for developing pyoderma gangrenosum (PG). So how can clinicians better manage their patients with PG? Explore this rare condition as Dr. Mary Katherine Cheeley is joined by Dr. Justin Cheeley, Assistant Professor in the Departments of General Internal Medicine and Dermatology and the Director of Inpatient Dermatology at the Emory School of Medicine.

Host: Matthew S. Keller MD
Host: Monica Schwartzman, MD, MS

Getting the proper treatment for patients with psoriasis and psoriatic arthritis can be life-changing. So how can clinicians help patients find the right medication? To discuss this topic together, Dr. Matthew Keller is joined by fellow ReachMD host, Dr. Monica Schwartzman, who is also a Rheumatologist.

Host: Michael Greenberg, MD
Guest: Jonathan S. Weiss, MD

Physician assistants (PAs) are licensed to practice medicine to provide many of the same services as a physician. And they may even train in dermatology. But what do we need to take into consideration when bringing a PA into a dermatology practice? Joining Dr. Michael Greenberg to discuss the ethics of this all-too-common situation is Dr. John Weiss, President and Co-Managing Partner at Georgia Dermatology Partners.

Host: Matthew S. Keller MD
Guest: Natasha Mesinkovska, MD, PhD

Alopecia areata affects more than 300,000 people in the United States each year, causing hair loss to the scalp, eyebrows, and eyelashes. But recent studies have shown that the Janus kinase inhibitor drug baricitinib can help significantly regrow hair for patients. To find out more about what this first-ever FDA approval of a systemic treatment could mean for patients with alopecia areata, Dr. Matthew Keller speaks with Dr. Natasha Mesinkovska, Associate Professor of Dermatology and Vice Chair for Clinical Research of Dermatology at University of California Irvine.

Host: Michael Greenberg, MD
Guest: Lynn McKinley-Grant, MD, FAAD

Psoriatic disease looks and feels different for people of color, and these differences may affect their diagnosis, treatment, and—by extension—quality of life. In fact, more than 50 percent of people with psoriatic arthritis experience a 2-year delay in diagnosis and a lower quality of life compared to white patients. So how can we help close the diagnostic gap and provide better care for our patients of color with psoriatic arthritis? To find out, Dr. Michael Greenberg is joined by Dr. Lynn McKinley-Grant, Associate Professor of Dermatology at Howard University College of Medicine.

Host: John Russell, MD
Guest: Randy Young, MD

As monkeypox continues to spread across non-endemic countries, how can we detect it in our patients? And what’s being done to stop the spread? Guest and fellow ReachMD Host Dr. Randy Young, a pulmonary disease and critical care medicine physician, joins Dr. John Russell to discuss what physicians should be looking for and how this virus has impacted public health.

Host: Michael Greenberg, MD
Guest: Esther Freeman, MD, PhD
Guest: Steven Chen, MD, MPH, MHPEd

With the recent rise of monkeypox cases around the world, dermatologists will be some of the first to evaluate and diagnose patients with the disease. So to help those on the frontlines, Dr. Esther Freeman, Director of Global Health Dermatology at Massachusetts General Hospital and Dr. Steven Chen, Assistant Professor of Dermatology at Harvard Medical School, share what dermatologists need to know about monkeypox.

Host: Michael Greenberg, MD
Guest: Brook Brouha, MD, PhD

How might genomics help us provide better care for our patients? Joining Dr. Michael Greenberg to share how he’s utilizing genomics in practice is Dr. Brook Brouha, a dermatologist and dermatopathologist at West Dermatology in San Diego, California.

Host: Matthew S. Keller MD
Guest: Michael Greenberg, MD

Are you looking to increase business at your dermatology practice? One simple solution is practicing goodness—in other words, being good and kind to your patients and their families. Joining Dr. Matthew Keller to explain why goodness is the best practice builder is fellow ReachMD Host Dr. Michael Greenberg.